Chelation therapy in beta-thalassemia: an optimistic update (Q34404499)

2 August 2017

1 reference

title

Chelation therapy in beta-thalassemia: an optimistic update (English)

1 reference

2 August 2017

0 references

1 reference

Giardina PJ

1

1 reference

PubMed ID

11605171

2 August 2017

Grady RW

series ordinal

2

1 reference

2 August 2017

1 October 2001

1 reference

2 August 2017

Seminars in Hematology

1 reference

2 August 2017

38

1 reference

2 August 2017

4

1 reference

2 August 2017

360-366

1 reference

Meta-analytic review of the clinical effectiveness of oral deferiprone (L1).

2 August 2017

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Results of long‐term deferiprone (L1) therapy: a report by the International Study Group on Oral Iron Chelators

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

A novel delivery system for continuous desferrioxamine infusion in transfusional iron overload

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Alternate use of deferiprone and desferrioxamine in primary school children with thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Sequential use of deferiprone and desferrioxamine in primary school children with thalassaemia major in Turkey

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Deferiprone: a review of its clinical potential in iron overload in beta-thalassaemia major and other transfusion-dependent diseases

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Evaluation of a new method of administration of the iron chelating agent deferoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Survival and disease complications in thalassemia major.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Survival and morbidity in transfusion-dependent thalassemic patients on subcutaneous desferrioxamine chelation. Nearly two decades of experience.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

A multi-center safety trial of the oral iron chelator deferiprone.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Safety profile of the oral iron chelator deferiprone: a multicentre study

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Oral iron chelation with deferiprone

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Therapy for beta-thalassemia--a paradigm for the treatment of genetic disorders

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Results of long-term iron-chelating therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

HBED: a potential oral iron chelator

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Iron chelators for thalassaemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

ICL670A: a new synthetic oral chelator: evaluation in hypertransfused rats with selective radioiron probes of hepatocellular and reticuloendothelial iron stores and in iron-loaded rat heart cells in culture

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Pathophysiology of iron overload.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Design of orally active iron chelators

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Iron chelation therapy: the need for orally active drugs

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Diagnosis and management of iron-induced heart disease in Cooley's anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Iron-chelation therapy with oral deferiprone--toxicity or lack of efficacy?

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

An orally active iron chelator

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Long-term therapy with deferiprone

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

The beta-thalassemias

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Long-term trials of deferiprone in Cooley's anemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Iron-chelation therapy with oral deferiprone in patients with thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Comparison of oral iron chelator L1 and desferrioxamine in iron-loaded patients

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Survival in medically treated patients with homozygous beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Deferiprone (L1) associated neutropenia in beta thalassemia major: an Indian experience

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Chelation studies with 2,3-dihydroxybenzoic acid in patients with beta-thalassaemia major

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Oral iron chelators for the clinical management of iron overload. Current hopes and problems

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Evaluation of new iron chelators for clinical use.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

A trial to investigate the relationship between DFO pharmacokinetics and metabolism and DFO-related toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

The controversial role of deferiprone in the treatment of thalassemia.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

New trends in the treatment of beta-thalassemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Chelator-induced iron excretion in iron-overloaded marmosets

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Efficacy and Side Effects of Deferiprone (L1) in Thalassemia Patients Not Compliant with Desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Thalassemia in the next millennium. Keynote address.

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

New approaches to the management of hepatitis and endocrine disorders in Cooley's anemia

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

Combined therapy with deferiprone and desferrioxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0037-1963%2801%2990030-7

7 January 2021

10.1016/S0037-1963(01)90030-7

Identifiers

DOI

1 reference

2 August 2017

1 reference

PubMed ID

11605171